Development of a Novel In Vitro Assay (ALS Assay) for Evaluation of Vaccine-Induced Antibody Secretion from Circulating Mucosal Lymphocytes

H. SUNNY CHANG* AND DAVID A. SACK†

Vaccine Testing Unit, Department of International Health, Johns Hopkins University School of Hygiene and Public Health, Baltimore, Maryland 21205

Received 24 April 2000/Returned for modification 4 December 2000/Accepted 17 January 2001

We describe here a novel method for measuring in vitro antibody secretion from the tissue culture of human B lymphocytes in peripheral blood mononuclear cells (PBMC) after oral vaccination with a killed cholera vaccine. Enzyme-linked immunosorbent assay (ELISA) titers of the antibody secreted in the cell supernatant were determined. The validation results demonstrated that human PBMC remained viable and continued to secrete antibodies (total immunoglobulin A [IgA] and IgG) for up to 4 days of incubation at 37°C with 5% CO2 in cell cultures. The secreted antibody concentration correlated positively with the PBMC concentration and incubation time in the tissue culture and correlated negatively with the storage time of the whole blood at room temperature. In vitro assay of secreting antibody in the lymphocyte supernatant (i.e., the ALS assay) is capable of detecting specific antibody response after oral vaccination with a killed whole-cell-plus-B-subunit cholera vaccine (WC-B) in healthy adults in a phase I clinical trial. Postimmunization PBMC secreted antibodies to cholera toxin in the cell supernatants. Antibody production did not require any in vitro antigen stimulation. In the ALS assay, antigen-specific antibody titers of prevaccination samples were barely detectable, whereas serum antitoxin ELISA titers in background of prevaccine samples were significantly higher than the ALS titers. We conclude that, without any in vitro antigen stimulation after vaccination, PBMC secrete antibodies into the supernatants in the ALS assay. This assay can quantitatively measure the antigen-specific antibody production from the PBMC culture in postvaccination blood samples.

Postvaccination immunity is generally assessed via the use of antibodies in serum, but it is impossible to distinguish between recently produced antibodies and preexisting antibodies. Antibody levels in serum do not represent the latest immune responses accurately, because serum antibodies include the accumulated soluble antibodies that were induced by previous exposure to antigens.

Recent antigen exposure of mucosal T and B cells induces proliferation and differentiation of these cells (14, 25). The activated T and B cells circulate through the thoracic duct into the blood and eventually return to common mucosal sites, such as the lamina propria of the intestine, as matured plasma cells (2, 17, 20, 22, 23, 26).

To develop a sensitive surrogate for assaying local immunity, the lymphocytes traveling from local mucosal areas to the systemic blood circulation are used by methods for in vitro laboratory evaluations such as ELISPOT (6–10, 12, 15, 18; Lowry et al., letter). ELISPOT measures the results of specific antibody-secreting cells (ASC) on a spot-forming gel (11–13, 15, 18; Lowry et al., letter). ELISPOT measures the number of antibody producing cells per 10^6 PBMC following oral vaccination (11, 16). The quantification of antibodies secreted by a fixed concentration of PBMC is as important as the enumeration of ASC.

We describe here a novel method for measuring in vitro secreting antibody from human lymphocyte’s supernatant, i.e., the ALS assay, which directly measures antibody secretions from PBMC of peripheral blood on a microtiter plate. The ALS assay has been validated by the measurement of total immunoglobulin A (IgA) and IgG production under a series of tissue culture conditions (PBMC inoculation concentration, incubation time, and blood storage time). Then, 10^7 PBMC was used to determine the antigen-specific antibodies to cholera toxin after the oral vaccination of a licensed Vibrio cholerae vaccine in a phase I clinical trial.

Two formulations of a killed whole-cell-plus-B-subunit cholera vaccine (WC-B) were used to immunize 12 healthy adults. A standard liquid formulation of the vaccine was stored continuously at 4°C, and a spray-dried formulation of the vaccine was placed at room temperature for 30 days. Volunteers were randomized to receive two doses of either vaccine in a double-blind manner. The vaccine induced an elevation in cholera toxin-specific antibodies in sera and induced secretive toxin-specific antibodies in the ALS assay. The ALS assay is potentially an accurate surrogate for measuring recent antibody response and for the diagnosis of recent infections in humans.

**MATERIALS AND METHODS**

**Isolation of human PBMC.** To perform the ALS assay, PBMC were isolated from blood samples via Histopaque layering. A portion (30 ml) of blood was collected in citrate anticoagulant and diluted with sterile phosphate-buffered saline (PBS; Sigma) at up to 40 ml in a 50-ml sterile conical tube. The diluted blood was split into two tubes and layered onto 10 ml of Histopaque-1077 (Sigma H-8889) in a sterile 50-ml conical tube without mixing. These tubes were centrifuged at 1,200 (290 × g) for 30 min. The mononuclear cell layer was trans-
ferred to a new tube and washed with 1× PBS. The cells were centrifuged at 1,200 rpm for 5 min in 40 ml of PBS. The cell pellet was resuspended in 10 ml of PBS. To determine the PBMC concentration, PBMC were stained with trypan blue and counted with a hemocytometer.

The cells were pelleted by centrifugation (1,200 rpm [290 × g], 5 min) and adjusted to a concentration of 10⁷ cells per ml with complete RPMI 1640 medium.

Complete RPMI 1640 medium for ALS assay and T-cell proliferation. A total of 50 ml of 10% fetal calf serum (FCS; C-Six Diagnostics, Inc.), 10 ml of 2% t-glutamine (Quality Biochemicals, Inc. [catalog no. 118-084-004]), and 5 ml of antibiotics (ampicillin, 100 μg/ml; streptomycin, 100 μg/ml; 1% [Mixed]; Quality Biochemicals, Inc. [catalog no. 129-096-050]) was added to every 500 ml of RPMI medium using a sterile technique. The medium was filtered via a 0.22-μm-pore-size filter if a precipitate appeared. The complete medium was stored at 4°C for up to 30 days. To do the T-cell proliferation assay, the same RPMI 1640 complete medium was used except that FCS was replaced with 25% of human serum (5%; C-Six Diagnostics, Inc.).

**Culture of cells for the ALS assay and assay for T-cell proliferation.** The condition of the in vitro culture of PBMC was defined by (i) PBMC concentration and volume during initial inoculation, (ii) incubation time, (iii) temperature, and (iv) air quality. A portion (1 ml) of the desired concentration of PBMC in complete RPMI 1640 medium was inoculated under sterile conditions into the wells of a 24-well tissue culture plate. The cells were then incubated at 37°C in 5% CO₂ for up to 96 h. At the end of the incubation period, the tissue culture fluid was removed and stored at −20°C.

**Storage of human blood samples and viability counts at room temperature.** To assess the yield of PBMC from human blood samples which were stored for different numbers of days at room temperature, blood samples from three healthy, nonvaccinated volunteers were collected and stored at 25°C for up to 3 days while remaining in the original vacutainer tubes. Equal-volume aliquots were processed at day 0, day 1, day 2, and day 3 for PBMC isolation. The total number of viable cells was counted using a microscope, a hemocytometer, and trypan blue staining.

**ELISA for measuring IgA and IgG antibodies of anti-V. cholerae toxin (CTB) subunit and LPS (V. cholerae LPS).** Antibodies to anti-lipopolysaccharide (LPS)-specific IgA and IgG and IgM levels were measured by the enzyme-linked immunosorbent assay (ELISA) method using Gm1 and LPS as capture antigens. Microtiter 96-well, low-binding plates were first coated with a 100 μl of either 50 μg of Gm1 (Sigma) or 50 μg of V. cholerae LPS (Inaba Stn; Sigma) per ml in PBS overnight. The plates were then washed twice with 1× PBS and blocked with 100 μl of 0.1% bovine serum albumin (BSA)-PBS for 30 min at 37°C. The plates were washed three times with PBS-0.05% Tween 20. For the antigen assay, the Gm1 plates were supplemented with 100 μl of a 0.5-μg/ml concentration of cholera toxin B (CTB).

Test samples from the serum of volunteers or ALS supernatants were serially diluted in the plates using 0.1% BSA-PBS-Tween solution as a diluent. After 30 min of incubation, the plates were washed twice with PBS-Tween. The plates were then blocked with 100 μl of anti-human IgG or anti-human IgA conjugated with horse-radish peroxidase (Jackson Laboratories) diluted in 0.1% BSA-PBS-Tween was added to each well. After the mixtures were washed, 100 μl of o-phenylenediamine (OPD; 1 mg/ml; Sigma) in 0.1 M sodium citrate buffer (pH 4.5) with 30% H₂O₂ (4 mol/l) was added to each well. After 30 min of incubation, the plates were washed twice with PBS-Tween. The plates were then blocked with 100 μl of either 100 μl of the recombinant B subunit of cholera toxin (3).

The dry vaccine was prepared from the same lot of the vaccine liquid. To prepare the dry formulation, the same vaccine was mixed with syrup of the CeraVacc buffer and sprayed dried. One dose contained 10 g of dry powder, which was dissolved in 200 ml of water at the time of immunization (3).

To administer the liquid formulation, 3 ml of liquid vaccine (one dose) was mixed with 150 ml of Samarin buffer in a cup and was ingested orally, according to the instructions on the packet. To administer the dry vaccine, one dose (10 g of dry powder) was mixed with 200 ml of water and ingested orally. Eating and drinking was not allowed for 1 h before and after vaccination (3).

The volunteers were randomly assigned to receive two doses of either the dry vaccine or the liquid vaccine. Six volunteers were each in group. Peripheral blood was collected by using a Vacutainer on days 0, 14, 21, and 24. Samples (20 ml) of blood were obtained by using a Vacutainer into sodium citrate tubes (Blue Top; Becton Dickinson), and 10 ml without coagulant was placed in a Red Top tube and stored at 25°C.

**ALS assay for V. cholerae antitoxin IgA and IgG during an oral cholera vaccine clinical trial.** To apply the ALS assay for measurement of the antigen-induced specific humoral response, PBMC were collected during a safety and immunogenicity trial of an oral killed cholera vaccine in healthy adult volunteers. A standard liquid formulation of the Vaccine and a spray dry formulation of the vaccine were compared. The liquid formulation was stored continuously at 4°C, but the dry vaccine was placed at room temperature for 30 days. Volunteers were randomized to receive two doses of vaccine in a double-blind manner. Healthy volunteers between 18 and 50 years of age were recruited from the Baltimore area. Each volunteer received two doses of vaccine. Serum and PBMC were collected at days 0, 14, 21, and 24 after administration of dose one. The ALS assay was used to measure antitoxin IgA and IgG. (The complete evaluation of the vaccine trial will be reported elsewhere.)
TABLE 1. Stability of human PBMC at 25°C for up to 72 h

| Time (h) | Avg PBMC yieldb ± SD (10^6/10 ml of blood) | P | Avg T-cell proliferationa ± SD |
|----------|------------------------------------------|---|-------------------------------|
| 0        | 151 ± 26                                 |    | 33.9 ± 12.7                   |
| 24       | 132 ± 46                                 | 0.29 | 37.6 ± 19.2                   |
| 48       | 142 ± 27                                 | 0.35 | 6.9 ± 10.2                    |
| 72       | 103 ± 57                                 | 0.13 | 9.8 ± 12.8                    |

a Three human normal blood samples were obtained with citrate anticoagulant and stored at 25°C. Each day, 10 ml of each sample was processed for PBMC isolation up to 72 h via hemocytometer under a ×36 microscope lens. Average PBMC yields and standard deviations of the three volunteers are reported in the table. A one-tailed t test was performed (P) between day 0 and any of the other days for the total viable cell counts.

b Three blood samples from healthy volunteers were collected (no vaccination) and stored at 25°C. These samples were processed at day 0, day 1, day 2, and day 3, and the cell concentrations were adjusted to 10^6 cells/ml. On a 96-well tissue culture plate, 100 μl of each PBMC sample was added to each well. To stimulate PBMC, 100 μl of a 2-ng/ml concentration of ConA per ml was added to each well. The cells were harvested and counted for H3 incorporation. The results are expressed as the ratio of sample counts with ConA to corresponding control counts without ConA.

**RESULTS**

Human blood sample storage and viability counts as determined with a hemocytometer under a ×36 lens at room temperature. A 10-ml portion of blood yielded about 150 × 10^6 PBMC after storage at room temperature up to 48 h. By day 3, the PBMC yield dropped by about 30% on average (Table 1 and Fig. 1).

Negative control: antibody level in PBMC. There was no detectable antigen-specific or nonspecific IgA or IgG in 10^7 sonicated PBMC from the V. cholerae-vaccinated-volunteer blood samples (data not shown).

Effect of blood storage on total IgA secretion at room temperature. The results indicated that storage was a negative factor for IgA production in the ALS assay. After 24 h of storage, the same sample’s total IgA yield dropped from 450 to 50 μg/ml in the in vitro cultures. However, samples stored for 1, 2, and 3 days produced similar and significant amounts of total IgA (50 μg/ml) in the supernatants.

The average total IgA level of two normal human blood samples, which were stored at 25°C before PBMC processing, was determined. The supernatants were taken after 96 h of incubation, and the initial concentrations were 7 logs of the cells. The total IgA levels on storage days 0, 1, 2, and 3 were 459 (range, 417 to 500), 62 (range, 62 to 62), 49 (range, 38 to 60), and 51 (range, 44 to 59), μg/ml, respectively.

Effect of blood storage on T-cell proliferation at room temperature. PBMC from blood samples stored up to 24 h were highly sensitive to ConA stimulation. These PBMC produced a high and sustained level of T-cell proliferation (a 33-fold increase in H3 incorporation compared to non-ConA-stimulated controls). However, after blood storage for 24 h, the T-cell proliferation ability of the PBMC dropped significantly from a titer of 33-fold to 7-fold in H3 (1/20; stock, 1 uCri) incorporation compared to non-ConA-stimulated controls (Table 1 and Fig. 2).

Total IgA secretion increases with the increase of PBMC concentrations in the ALS assay. When cells were incubated for 96 h in tissue culture, the total IgA production increased exponentially with the increase in the concentration of PBMC. At from 10^5 to 10^7 cells, the log of the IgA concentration was linearly related to the log of the initial cell concentration. The slope appeared to increase with higher cell concentrations (Table 2).

Total IgA secretion increases with the increase of PBMC incubation time in the ALS assay. Total IgA secretion increased linearly with time of incubation (2 to 4 days) when 10^7 PBMC of day 0 blood were used in the ALS assay. The slope appeared to increase with longer incubation days. The total IgA from the samples of two normal human volunteers was measured in the supernatants of an ALS assay following incubation for 2, 3, and 4 days, and the results, obtained with a 1-ml
portion of PBMC (10^7 cells per ml), were averaged together. The IgA levels were determined to be 116 (range, 74 to 157), 197 (range, 120 to 274), and 459 (417 to 500) μg/ml for incubation days 2, 3, and 4, respectively.

**Linear regression model.** There was a significant linear relationship between the log IgA and log cell concentrations and the incubation time. The log IgA in (micrograms per milliliter) is the dependent variable. The independent variables are the incubation time and the log cell concentration (based on day 0 storage data). The regression equation is as follows: \( \text{log IgA (μg/ml)} = -4.632 + 0.424 \times \text{incubation day} + 0.794 \times \log \text{concen} \)

According to this model, if the incubation time increases by 1 day, 0.424 log of total IgA will be secreted. If the cell concentration is increased by 1 log, 0.794 log of total IgA would be secreted. The linear regression model was highly significant, with an \( F \) score of 61.9, a \( P \) value of 0.000, and a regression coefficient of 0.89 (Table 3). The model was validated by its randomness residual distribution (Fig. 3).

**ALS IgA anti-CTB for cholera vaccine volunteers.** Immunization with either formulation of the oral killed cholera vaccine in humans induced specific IgA anti-CTB 14 days after the first dose and 7 days after the second dose in the ALS assay. The peak of the IgA ALS titer was at day 21 and started to decrease by day 24 (Table 4). The liquid formulation of the oral vaccine induced significantly higher IgA to CTB than the dry formulation (Table 4).

However, the titers in serum showed a very different result from those of the ALS assay. The titers in serum showed higher titers with the dry formulation. An antibody titer continuously increased until day 24 (Table 4).

**ALS IgG anti-CTB.** In comparison to the IgA response, the ALS IgG anti-CTB response of the liquid formulation was significantly higher than that of the dry formulation. Both formulations induced significant ALS antibody response 14 days after the first dose and 7 days after the second dose. The peak of ALS IgG anti-CTB response was at day 21 and dropped at day 24 (Table 4). Similar to the IgA response, the dry vaccine induced IgG titers in serum that were higher than those with the liquid vaccine. The titers in serum continuously increased until day 24 (Table 4).

**DISCUSSION**

ALS, a specific, reliable, and accurate immunoassay, was developed for the evaluation of fresh antibody production from circulating mucosal secreting B lymphocytes. In the human trial described here, the ALS assay detected the significant antitoxin increases induced by either formulation of the oral vaccine. The ALS results indicated a peak booster antitoxin response at day 21, which is 7 days after the second dose, that started to decrease at day 24. (Complete results for this clinical trial will be reported separately.)

By assaying only antibodies secreted by circulating cells, the ALS method controlled the confounding effect of accumulative

---

**TABLE 2.** PBMC concentration versus total IgA concentration

| Log concn | Mean log IgA concn (μg/ml) (range) |
|-----------|----------------------------------|
| 7         | 2.66 (2.62–2.70) 2.30 (2.08–2.44) 2.06 (1.87–2.20) |
| 6         | 1.66 (1.47–1.79) 1.09 (1.05–1.13) 0.82 (0.58–0.97) |
| 5         | 1.29 (1.04–1.45) 0.80 (0.61–0.93) 0.26 (0.00–0.45) |

* Average data of two normal human PBMC samples adjusted with 1 ml of the initial concentration at log 7, 6, and 5 of cells per milliliter. Supernatants were collected after 4 days of incubation. Total IgA was measured and is expressed in log IgA (micrograms/milliliter, with range from lowest to highest).

**TABLE 3.** Regression model summary

| Parameter         | Coefficient | t     | P     |
|-------------------|-------------|-------|-------|
| Constant          | -4.632      | 8.473 | 0.000 |
| Incubation days   | 0.424       | 6.244 | 0.000 |
| Log concn         | 0.794       | 9.815 | 0.000 |

\( F = 61.916; P = 0.000; R^2 = 0.88; \) Predictors, log concentration and incubation days; dependent variable, log total IgA in micrograms/10^7 cells.
antibody in the serum samples, which contain both recent and preexistent soluble antibodies. Since the serum portion of the blood sample has been removed in the ALS assay, this assay measures only the secreting antibodies. When the ALS assay was performed, antibody titers from prevaccination samples were barely detectable, but background titers in serum were found in prevaccination samples.

In the ALS assay, vaccine-activated mucosal lymphocytes

![Scatterplot](image)

**FIG. 3.** Residual scatter plot for the regression model showing predictive value versus residuals.

**TABLE 4.** Antitoxin response in serum and ALS assays after oral cholera vaccination

| Antitoxin assay and day | Dry formulation | Liquid formulation |
|------------------------|-----------------|--------------------|
|                        | GMT (range)     | Fold increase to day 0 | GMT (range) | Fold increase to day 0 |
| Serum IgA antitoxin    |                 |                    |              |                      |
| 0                      | 35 (6–219)      | 1                   | 32 (13–78)  | 1                     |
| 14                     | 89 (23–347)     | 2.5                 | 46 (17–120) | 1.4                   |
| 21                     | 269 (148–490)   | 7.7                 | 123 (60–251)| 3.8                   |
| 24                     | 251 (132–479)   | 7.2                 | 174 (78–427)| 5.4                   |
| Serum IgG antitoxin    |                 |                    |              |                      |
| 0                      | 120 (58–251)    | 1                   | 93 (54–162)| 1                     |
| 14                     | 191 (78–468)    | 1.6                 | 148 (60–363)| 1.6                   |
| 21                     | 389 (123–1230)  | 3.2                 | 339 (155–741)| 3.6                   |
| 24                     | 575 (263–1230)  | 4.8                 | 372 (78–776)| 4                     |
| ALS IgA antitoxin      |                 |                    |              |                      |
| 0                      | 1 (0.2–1.12)    | 1                   | 0.86 (0.28–2.57)| 1                     |
| 14                     | 0.91 (0.43–2.34)| 0.9                 | 1.27 (0.43–3.80)| 1.5                   |
| 21                     | 1.92 (0.66–5.75)| 1.9                 | 4.38 (0.91–20.89)| 5.1                   |
| 24                     | 0.66 (0.55–1.02)| 0.7                 | 2.64 (0.55–12.88)| 3.1                   |
| ALS IgG antitoxin      |                 |                    |              |                      |
| 0                      | 0.28 (0.07–1.05)| 1                   | 0.66 (0.13–3.31)| 1                     |
| 14                     | 0.47 (0.09–2.4) | 1.7                 | 1.44 (0.49–4.27)| 2.2                   |
| 21                     | 1.30 (0.63–2.69)| 4.6                 | 4.22 (1.07–16.6)| 6.4                   |
| 24                     | 0.68 (0.32–1.48)| 2.4                 | 3.50 (0.71–17.38)| 5.3                   |

*Anti-CTB IgG and IgA levels from volunteer sera were measured via ELISA of GM1-CTB-coated plates. Titers were determined by use of a hyperbolic curve. Then the geometric mean titer (GMT) of same-day determinations for each group of volunteers were calculated by using Excel software. The fold increase values are also reported.*

*Copyright 2022, American Society for Microbiology. All Rights Reserved.*
were cultured in vitro for 2 to 4 days. The secreted antigen-specific immunoglobulins in the supernatants of tissue culture were qualitatively and quantitatively measured. These PBMC are believed to be the circulating mucosal lymphocytes. ALS measures the change in host antibody response with the amount of nonstimulated, in vitro antibody produced at different postvaccination time points. This test allowed us to monitor the magnitude of the mucosal B-cell’s antibody production strength during the course of immunization.

Antibody production of lymphocytes requires multiple signals and optimal cognitive interactions, such as receptor engagement between antigen-presenting cells (APC), T cells, and B cells. The isolated PBMC layer from blood samples contains a mixture of these components. In the ALS system, antibody production is enhanced by cell concentration and incubation time synergistically. High concentrations of cells in a contained space enhances the cognitive distance of cell-to-cell interaction. As the efficiency of cell interaction increased, antibody secretion increased exponentially. When the blood samples were subjected to a long storage condition such as at room temperature for 2 days, it is possible that some key components, such as the cytokines necessary for antibody secretion, start to deteriorate. Although T-cell proliferation had been effective after 24 h of storage, the total antibody production ability dropped significantly after 24 h. Therefore, the storage of blood samples was certainly a sensitive factor for the ALS assay. If one could accurately determine which components were defective, preservation measures could be taken and/or supplements could be added to further extend the in vitro antibody secretion for a longer time period, which would have tremendous practical value for the processing of large numbers of blood samples.

Since 1963, immunoglobulin secretion at the cellular level has been assayed by hemolytic plaque assay (1). Hemolytic assay can detect cells secreting complement-binding antibodies against erythrocytes (4, 5, 24). This assay has limitations when it is applied to soluble antigens passively adsorbed to red blood cells (24). Inconsistent results had generally been associated with difficulty in coupling antigen efficiently to red cells (4, 5, 24). Additionally, the hemolytic assay did not permit quantification of secreted molecules. ELISPOT is a qualitative assay for ASC. It requires a subjective reading of the formed spots.

The ALS assay quantifies the amount of antibody secreted and the strength of the antibody production for a fixed number of PBMC. Logistically, ALS assay does not require live bacteria during testing as the vibriocidal tests. Compared to the ASC assay, the ALS assay uses antibody supernatants of the PBMC as its final specimens rather than the PBMC. In terms of the storage of samples, cells may be stored at −70°C for up to 6 months for the ASC assay, whereas ALS supernatants can be stored at 4°C or −20°C for a much longer time. The ALS assay final result is based on readings from the ELISA reader rather than the subjective determinations of spot formation on gels in the ASC assay and turbidity in the vibriocidal assay. The major limitation of the ALS assay is the requirement of the use of fresh blood to yield a high quantity and quality of PBMC.

This assay is specifically useful for the determination of a recent immune response during vaccine trials in areas where the disease is endemic and where the population already has preexisting serum titers. It could also be used as a diagnostic method for identifying recent infections.

ACKNOWLEDGMENTS

We thank Lou Bourgeois and Janet Shimko for their excellent technical review of the manuscript and Keerti Shah, Mark Steinhoff, and W. B. Greenough III for their technical advice.

REFERENCES

1. Alam, M., S. Miyoshi, I. Maruo, C. Ogawa, and S. Shinoda. 1994. Existence of a novel hemagglutinin having no protease activity in Vibrio mimicus. Microbiol. Immunol. 38:467–470.
2. Brenner, D. J., F. W. Hickman-Brenner, J. V. Lee, A. G. Steigerwalt, G. R. Fanning, D. G. Hollis, J. J. Farmer III, R. E. Weaver, S. W. Joseph, and R. J. Seidler. 1983. Vibrio furnissii (formerly aerogenic biogroup of Vibrio flavinus), a new species isolated from human feces and the environment. J. Clin. Microbiol. 18:816–824.
3. Carvalho, I. T., V. Magalhaes, N. C. Leal, V. Melo, and M. Magalhaes. 1994. Vibrio fluvialis attaches to but does not enter HeLa cell monolayers. Mem. Inst. Oswaldo Cruz 89:221–233.
4. Chowdhury, M. A., R. T. Hill, and R. R. Colwell. 1994. A gene for the enterotoxin zonula occludens toxin is present in Vibrio mimicus and Vibrio cholerae O139. FEMS Microbiol. Lett. 119:377–380.
5. Coelho, A., H. Momen, A. C. Vicente, and C. A. Salles. 1994. An analysis of the V1 and V2 regions of Vibrio cholerae and Vibrio mimicus 16S rDNA. Res. Microbiol. 145:151–158.
6. Czerkinsky, C., G. Andersson, H. P. Ekre, L. A. Nilsson, L. Klareskog, and O. Ouchterlony. 1988. Reverse ELISPOT assay for clonal analysis of cytotoxic T cells. J. Immunol. Methods 110:29–36.
7. Czerkinsky, C., Z. Moldovanu, J. Mestecki, L. A. Nilsson, and O. Ouchterlony. 1988. A novel two colour ELISPOT assay. J. Immunol. Methods 115:5–17.
8. Czerkinsky, C., L. A. Nilsson, H. Nygren, O. Ouchterlony, and A. Tarkowski. 1983. A solid-phase enzyme-linked immunosorbent (ELISPOT) assay for enumeration of specific antibody-secreting cells. J. Immunol. Methods 65:109–121.
9. Czerkinsky, C. C., L. A. Nilsson, A. Tarkowski, O. Ouchterlony, S. Jeansson, and C. Greter. 1984. An immunoenzyme procedure for enumerating fibronectin-secreting cells. J. Immunol. 5:291–302.
10. Czerkinsky, C. C., A. Tarkowski, L. A. Nilsson, O. Ouchterlony, H. Nygren, and C. Greter. 1984. Reverse enzyme-linked immunosorbent assay (ELISPOT) for the detection of cells secreting immunoreactive substances. J. Immunol. Methods 72:489–496.
11. Friman, V., M. Quiding, C. Czerkinsky, I. Nordstrom, L. Larsson, D. Ericsson, J. Bjorkander, K. The man, A. Kilander, J. Holmgren, et al. 1994. Intestinal and circulating antibody-forming cells in IgA-deficient individuals after oral cholera vaccination. Clin. Exp. Immunol. 95:222–226.
12. Hickman, F. W., J. J. Farmer III, D. G. Hollis, G. R. Fanning, A. G. Steigerwalt, R. E. Weaver, and D. J. Brenner. 1982. Identification of Vibrio cholerae sp. nov. from patients with diarrhea. J. Clin. Microbiol. 15:395–401.
13. Holmgren, J., C. Czerkinsky, N. Lycke, and A. M. Svennerholm. 1992. Macosal immunity: implications for vaccine development. Immunobiology 184:157–179.
14. Hornquist, E., and N. Lycke. 1995. Cholera toxin increases T lymphocyte responses to unrelated antigens. Adv. Exp. Med. Biol. 371B:507–513.
15. Morris, J. G., Jr., H. G. Miller, R. Wilson, C. O. Tacket, D. G. Hollis, F. W. Hickman, R. E. Weaver, and P. A. Blake. 1982. Illness caused by Vibrio damselae and Vibrio hollisae. Lancet 1:6294.
16. Nilsson, D. E., V. Friman, K. Theman, J. Bjorkander, A. Kilander, J. Holmgren, L. A. Hanson, and P. Brandtzaeg. 1993. B-cell activation in duodenal mucosa after oral cholera vaccination in IgA-deficient subjects with or without IgG subclass deficiency. Scand. J. Immunol. 38:201–208.
17. Nishibuchi, M., and R. J. Seidler. 1983. Medium-dependent production of extracellular enterotoxins by non-O1 Vibrio cholerae, Vibrio mimicus, and Vibrio fluvialis. Appl. Environ. Microbiol. 45:228–231.
18. Quiding, M., I. Nordstrom, A. Kilander, G. Andersson, L. A. Hanson, Holmgren, J., and C. Czerkinsky. 1991. Intestinal immune responses in humans. Oral cholera vaccination induces strong intestinal antibody responses and interferon-gamma production and evokes local immunological memory. J. Clin. Investig. 88:143–148.
19. Rahman, M. M., F. Qadri, M. J. Albert, A. Hossain, and M. Mosihuzzaman. 1992. Lipopolysaccharide composition and virulence properties of clinical and environmental strains of Vibrio fluvialis and Vibrio mimicus. Microbiol. Immunol. 36:327–338.
21. Rank, E. L., I. B. Smith, and M. Langer. 1988. Bacteremia caused by *Vibrio hollisae*. J. Clin. Microbiol. 26:375–376.
22. Suthienkul, O. 1993. Bacteriophage typing of *Vibrio fluvialis*. Southeast Asian J. Trop. Med. Public Health 24:449–454.
23. Thekdi, R. J., A. G. Lakhani, V. B. Rale, and M. V. Panse. 1990. An outbreak of food poisoning suspected to be caused by *Vibrio fluvialis*. J. Diarrhoeal Dis. Res. 8:163–165.
24. Uchimura, M., and T. Yamamoto. 1992. Production of hemagglutinins and pili by *Vibrio mimicus* and its adherence to human and rabbit small intestines in vitro. FEMS Microbiol. Lett. 70:73–78.
25. Vajdy, M., and N. Lycke. 1993. Stimulation of antigen-specific T- and B-cell memory in local as well as systemic lymphoid tissues following oral immunization with cholera toxin adjuvant. Immunology 80:197–203.
26. Yamamoto, S., N. Okujo, Y. Fujita, M. Saito, T. Yoshida, and S. Shinoda. 1993. Structures of two polyamine-containing catecholate siderophores from *Vibrio fluvialis*. J. Biochem. 113:538–544.